Figure 5From: Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonistEffect of AZD8309 on FEV 1 after inhaled lipopolysaccharide (LPS). There was a similar peak fall in FEV1 at 1 h after challenge, then a more rapid recovery after AZD8309 compared to placebo, with a significant reduction in area under the curve (P < 0.05). The average values for the coefficient of variances were 14.4% and 15% for AZD8309 and placebo respectively. Mean values of 16 patients are shown.Back to article page